BNXT Share Price Performance
CA$0.64
0.32 (100.00%)
46.7% undervalued intrinsic discount
CA$1.20
Fair Value
Price CA$0.64
Ruhli CA$1.20
Fair ValueCA$1.20
Share Pricen/a
BioNxt Solutions Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
BNXT Community Narratives
RU
Fair Value CA$1.2 46.7% undervalued intrinsic discount
New era of chemotherapy
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
New era of chemotherapy
BioNxt is developing two platform technologies: a sublingual thin-film technology (ODF) for smart drug delivery and a novel chemotherapy platform in which the active ingredient is activated directly in the tumor—targeting and killing cancer cells while sparing healthy cells. The ODF technology is protected by a European broad patent (intention-to-grant, May 2025), covering a wide range of sublingual active ingredients and is being nationalized in key markets.Read more
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
RU
CA$1.2
46.7% undervalued intrinsic discount
Ruhli's Fair Value
Revenue
400% p.a.
Profit Margin
15.34%
Future PE
24.62x
Price in 2030
CA$1.6
Trending Discussion
Recently Updated Narratives
RU
New era of chemotherapy
Fair Value: CA$1.2 46.7% undervalued intrinsic discount
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioNxt Solutions Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.051
- 100.00%
- -39,034.10%
- -100.3%
About BNXT
- Founded
- 2017
- Employees
- n/a
- CEO
- WebsiteView website
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
